Reference
1. Konstantinides SV, Torbicki A,
Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV,
Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E,
Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil
P, Vonk Noordegraaf A, Zamorano JL, Zompatori M. 2014 ESC guidelines on
the diagnosis and management of acute pulmonary embolism. Eur Heart J
2014; 35: 3033-69, 69a-69k.
2. Menichetti M, Rosso S, Menegatti E,
Pazzaglia M. Use of rivaroxaban in an elderly patient with
intermediate-low early mortality risk due to pulmonary embolism: a case
report. J Med Case Rep 2015; 9: 274.
3. Rivera-Lebron B, McDaniel M, Ahrar
K, Alrifai A, Dudzinski DM, Fanola C, Blais D, Janicke D, Melamed R,
Mohrien K, Rozycki E, Ross CB, Klein AJ, Rali P, Teman NR, Yarboro L,
Ichinose E, Sharma AM, Bartos JA, Elder M, Keeling B, Palevsky H,
Naydenov S, Sen P, Amoroso N, Rodriguez-Lopez JM, Davis GA, Rosovsky R,
Rosenfield K, Kabrhel C, Horowitz J, Giri JS, Tapson V, Channick R.
Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism:
Consensus Practice from the PERT Consortium. Clin Appl Thromb Hemost
2019; 25: 1076029619853037.
4. Yirgin G, Ates I Fau - Katipoglu B,
Katipoglu B Fau - Demir BF, Demir Bf Fau - Yilmaz N, Yilmaz N. Pulmonary
embolism due to synthetic cannabinoid use: Case report. Turk Kardiyol
Dern Ars 2018; 46: 411-13.
5. Pleticha J, Sutton EM.
Intraoperative Pulmonary Embolism: A Case Report Emphasizing the Utility
of Electrocardiogram. A A Case Rep 2017; 9: 349-52.
6. Marks PW. Hematologic
manifestations of liver disease. Semin Hematol 2013; 50: 216-21.
7. Shah NL, Intagliata NM, Northup PG,
Argo CK, Caldwell SH. Procoagulant therapeutics in liver disease: a
critique and clinical rationale. Nat Rev Gastroenterol Hepatol 2014; 11:
675-82.
8. Afdhal N, McHutchison J, Brown R,
Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia
associated with chronic liver disease. J Hepatol 2008; 48: 1000-7.
9. Bennani-Baiti N, Daw HA. Primary
hyperfibrinolysis in liver disease: a critical review. Clin Adv Hematol
Oncol 2011; 9: 250-2.
10. Senzolo M, Rodriguez-Castro KI,
Rossetto V, Radu C, Gavasso S, Carraro P, Zerbinati P, Sartori MT,
Simioni P. Increased anticoagulant response to low-molecular-weight
heparin in plasma from patients with advanced cirrhosis. J Thromb
Haemost 2012; 10: 1823-9.
11. Pugh Rn Fau - Murray-Lyon IM,
Murray-Lyon Im Fau - Dawson JL, Dawson Jl Fau - Pietroni MC, Pietroni Mc
Fau - Williams R, Williams R. Transection of the oesophagus for bleeding
oesophageal varices. Br J Surg 1973; 60: 646-49.
12. Imura S, Shimada M, Utsunomiya T.
Recent advances in estimating hepatic functional reserve in patients
with chronic liver damage. Hepatol Res 2015; 45: 10-9.
13. Konstantinides Sv Fau - Meyer G,
Meyer G Fau - Becattini C, Becattini C Fau - Bueno H, Bueno H Fau -
Geersing G-J, Geersing Gj Fau - Harjola V-P, Harjola Vp Fau - Huisman
MV, Huisman Mv Fau - Humbert M, Humbert M Fau - Jennings CS, Jennings Cs
Fau - Jimenez D, Jimenez D Fau - Kucher N, Kucher N Fau - Lang IM, Lang
Im Fau - Lankeit M, Lankeit M Fau - Lorusso R, Lorusso R Fau - Mazzolai
L, Mazzolai L Fau - Meneveau N, Meneveau N Fau - Ni Ainle F, Ni Ainle F
Fau - Prandoni P, Prandoni P Fau - Pruszczyk P, Pruszczyk P Fau -
Righini M, Righini M Fau - Torbicki A, Torbicki A Fau - Van Belle E, Van
Belle E Fau - Zamorano JL, Zamorano JL. 2019 ESC Guidelines for the
diagnosis and management of acute pulmonary embolism developed in
collaboration with the European Respiratory Society (ERS). Eur Heart J
2020; 41: 543-603.
14. Hum J, Shatzel JJ, Jou JH,
Deloughery TG. The efficacy and safety of direct oral anticoagulants vs
traditional anticoagulants in cirrhosis. Eur J Haematol 2017; 98:
393-97.
15. Intagliata NM, Henry ZH, Maitland
H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct Oral Anticoagulants
in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to
Traditional Anticoagulation. Dig Dis Sci 2016; 61: 1721-27.
16. Kubitza D, Roth A Fau - Becka M,
Becka M Fau - Alatrach A, Alatrach A Fau - Halabi A, Halabi A Fau -
Hinrichsen H, Hinrichsen H Fau - Mueck W, Mueck W. Effect of hepatic
impairment on the pharmacokinetics and pharmacodynamics of a single dose
of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol
2013; 76: 89-98.
17. Graff J, Harder S. Anticoagulant
therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban
and edoxaban and the thrombin inhibitor dabigatran etexilate in patients
with hepatic impairment. Clin Pharmacokinet 2013; 52: 243-54.